Catalyst Pharmaceuticals is a biotechnology business based in the US. Catalyst Pharmaceuticals shares (CPRX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.69 – a decrease of 2.09% over the previous day. Catalyst Pharmaceuticals employs 82 staff and has a market cap (total outstanding shares value) of $1.2 billion.
How to buy shares in Catalyst Pharmaceuticals
Choose a platform.If you're a beginner, our stock trading table below can help you choose.
Open your account.Provide your personal information and sign up.
Confirm your payment details.You'll need to fund your account with a bank transfer, debit card or credit card.
Search the platform for stock code:CPRX in this case.
Research stocks.The platform should provide the latest information available.
Buy your stocks.Place a market order or limit order with your preferred number of shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving license and a means of payment.
Our top picks for buying Catalyst Pharmaceuticals stock
Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Is it a good time to buy Catalyst Pharmaceuticals stock?
Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Use our graph to track the performance of CPRX stocks over time.
Share price volatility
Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $11.09 up to $22.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 1.1165. This would suggest that Catalyst Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Historical closes compared with the last close of 11.69
1 week (2023-09-25)
-3.63%
1 month (2023-09-01)
-16.02%
3 months (2023-06-30)
-13.02%
6 months (2023-03-31)
-29.49%
1 year (2022-09-30)
-8.89%
2 years (2021-10-01)
124.38%
3 years (2020-10-02)
283.28%
5 years (2018-10-02)
226.54%
Buy Catalyst Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is Catalyst Pharmaceuticals under- or over-valued?
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Catalyst Pharmaceuticals P/E ratio, PEG ratio and EBITDA
Catalyst Pharmaceuticals's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Catalyst Pharmaceuticals stocks trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of September 25, 2023 (21.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $154.5 million.
The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Frequently asked questions
We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Currently 6.313% of Catalyst Pharmaceuticals shares are held by insiders and 84.224% by institutions.
Catalyst Pharmaceuticals's fiscal year ends in December.
Catalyst Pharmaceuticals's address is: 355 Alhambra Circle, Coral Gables, FL, United States, 33134
It's as easy to sell Catalyst Pharmaceuticals as it is to buy! Here's how to sell Catalyst Pharmaceuticals stocks that you already own.
Open your investment app. If you've got one with desktop access, you can log in online
Go to your portfolio. This should be in the main menu
Find your shares. You may be able to search your portfolio
Choose how many you'd like to sell. You'll be able to review the price and see how much you'll receive
Sell your Catalyst Pharmaceuticals shares. Your investment platform will let you know when your shares are sold
Most dealing providers will let you use your debit card to top up your account and buy shares. The main ways are with a debit card, bank transfer or with Apple/Google Pay.
The easiest way to get hold of some Catalyst Pharmaceuticals shares is to sign up for a stock trading app and place a market order or basic order. This type of order tells the platform that you're interested, so it'll try to execute it as quickly as it can. It could take some time for the order to go through, especially if there's a lot of volatility in Catalyst Pharmaceuticals shares.
How likely would you be to recommend finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Advertiser Disclosure
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
Finder Award
Finder Award
